Evidence Explorer · MS-N279 · Unsupported cancer-treatment claim · Appraised November 9, 2026
Two randomized trials found no survival or quality-of-life benefit from shark-cartilage products in advanced cancer or stage III non-small cell lung cancer. Laboratory anti-angiogenesis ideas did not translate into improved patient outcomes.
Evidence at a glance
- Population: 379 people with unresectable stage III non-small cell lung cancer in a phase III trial; a separate placebo-controlled trial analyzed 83 people with advanced breast or colorectal cancer.
- Intervention: the standardized liquid shark-cartilage extract AE-941/Neovastat with chemoradiotherapy, or a powdered shark-cartilage product alongside standard care.
- Primary result: AE-941 did not improve median overall survival (14.4 versus 15.6 months; P=.73). The smaller trial found no survival or quality-of-life advantage.
- Evidence label: randomized negative evidence; no established cancer-control benefit.
What was studied
The phase III lung-cancer trial randomly assigned 188 participants to AE-941 and 191 to placebo while both groups received chemotherapy and thoracic radiation. Time to progression, progression-free survival and response also did not improve.
In the smaller blinded trial, the cartilage product was taken three or four times daily. Eighty-three evaluable participants with incurable breast or colorectal cancer showed no efficacy signal over placebo.
What this evidence cannot establish
These trials evaluated specific products, not every supplement sold as “shark cartilage.” Product variability does not rescue a negative result, and neither laboratory anti-angiogenesis findings nor the claim that sharks rarely develop cancer demonstrates clinical benefit.
Safety and practical context
NCI reports nausea, vomiting and gastrointestinal upset most often, with reports of hyperglycemia, weakness, hypercalcemia and hepatitis. Supplements may vary substantially by batch.
Using an animal-derived product also raises sourcing and sustainability questions. More importantly, substituting it for effective therapy can cost time that cannot be recovered.
Questions for the care team
- Is this the same formulation studied in a randomized trial?
- What established treatment or clinical trial could be delayed by using it?
- How would calcium, glucose, liver symptoms and supplement quality be monitored?
Sources and identifiers
- Randomized phase III AE-941 trial — PMID 20505152
- Randomized placebo-controlled advanced-cancer trial — PMID 15912493
- NCI Cartilage (Bovine and Shark) PDQ
Funding and conflicts: The phase III study was conducted through cooperative oncology and integrative-medicine research networks. Product-specific financial and conflict details were not fully re-extracted in this appraisal.
Source access and dates: Original reports, registry records and official safety sources available through the links above were checked November 9, 2026. Last literature search November 9, 2026.
Educational evidence summary, not individualized medical advice. Investigational or repurposed products should not replace established cancer treatment. Symptom, biomarker, laboratory or animal findings do not establish tumor control, recurrence prevention or longer survival.
